Center-Authored Papers

Filters: Author is Higano, Celestia  [Clear All Filters]
2012
Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS.  2012.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.. Nature medicine. Abstract
2013
Higano C.  2013.  Urological cancer: α-Emitting radium-223-additional choices, more unknowns.. Nature reviews. Clinical oncology. 10(11):612-3.
2014
Klotz L, Nabid A, Higano C, Ryanm C, Kebabdjian M, Chin J.  2014.  Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial.. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 8(11-12):E789-94. Abstract
2015
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin M-E, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT et al..  2015.  Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With . Clinical genitourinary cancer. 13(3):e191-8. Abstract
2016
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN et al..  2016.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T et al..  2016.  Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.. Nature medicine. Abstract
Hussain M, Tangen C, Higano C, Vogelzang N, Thompson I.  2016.  Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(3):280-285. Abstract